Similar drugsTo uncover
Dosage form: & nbspcapsules
Composition:

Per one capsule:

Active components:

Tilichinol *

50 mg

Tilichinola lauryl sulfate

(tilihinol N-dodecyl sulfate)

50 mg

Tilbroquinol

200 mg

Auxiliary components:

Lactose Monohydrate

90 mg

Corn starch

30 mg

Weight of capsule contents

420 mg

Capsule body:

Titanium dioxide (E171)

about 2%

Gelatin

up to 100%

Capsule cap:

Azorubine (E122)

about 0.6619%

Indigokarmin (indigotin (E132))

about 0.0286%

Titanium dioxide (E171)

about 0.6666%

Gelatin

up to 100%

* The total content of tilichinol in 1 capsule is from 0.0652 g to 0.0722 g (theoretically 0.0687 g).

Description:

Hard gelatin capsules number 1; the capsule body is opaque, white, the lid is opaque, dark red.

The contents of the capsules are a microcrystalline powder of grayish-yellow color.

Pharmacotherapeutic group:Antimicrobial medication combined
ATX: & nbsp
  • Other drugs for the treatment of amoebiasis and other protozoal infections
  • Pharmacodynamics:The pharmacological effect in chronic amebiasis is achieved due to the synergism of the amebicidal effect of 3 antiseptic substances included in the preparation Intetrix®. The drug acts in the lumen of the intestine and is used to treat intestinal amebiasis. Intetriks® is effective against vegetative forms of amoeba.Intetriks® does not disturb the balance of normal intestinal microflora.
    Pharmacokinetics:

    With oral administration of the drug, its absorption in the gastrointestinal tract is low, which allows maintaining an effective concentration in the lumen of the intestine.

    The maximum concentration in the plasma after taking the capsules is observed after 3-4 hours. Half-life is about 10 hours. The maximum excretion is determined after 12-24 hours. The entire preparation is withdrawn after 48 hours.

    In healthy volunteers, as well as in patients, tilichinol and tilbroquinol are rapidly absorbed, conjugated in the liver (1st path of metabolism) before entering the systemic circulation.

    Both substances are rapidly excreted in the urine: about 40% and 80% of the dose for tilichinol and tilbroquinol, respectively, mostly (99%) in a combined form.

    Pharmacokinetic parameters do not depend on the frequency of administration. Cumulation of tilichinol and tilbroquinol is low (cumulation coefficient less than 1.5). In a state of equilibrium, the parameters of excretion of tilichinol are close in value in healthy volunteers and in patients: the half-life is 3.3 h ± 1.9 and 3.1 h ± 1.8, respectively.

    The difference between tilichinol and tilbroquinol is as follows:

    - after repeated application in serum samples in an unchanged form only tilbroquinol is found;

    - Tilichinol (free or in conjugated form) is excreted in the urine in a much larger amount and faster than tilbroquinol.

    All this suggests that tilbroquinol in free and in conjugated forms is more active in the body than tilichinol.
    Indications:Adults: chronic intestinal amoebiasis (in combination with drugs acting on tissue forms of amoebae), amoebozoitelstvo (luminal forms of amoebae).
    Contraindications:

    - Children under 18 years;

    - Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

    - simultaneous use with drugs containing derivatives of hydroxyquinoline;

    - pregnancy;

    - the period of breastfeeding;

    - individual hypersensitivity to the components of the drug.

    Carefully:

    Liver failure.

    Pregnancy and lactation:

    When carrying out animal studies, the teratogenic effect was not detected. At present, there is insufficient data to estimate the potential risk of congenital malformations or the fetotoxic effect of the drugwhen administered during pregnancy.

    Studies of the effect of the drug on lactation in animals have not been conducted.

    Therefore, the use of Intetriks ® during pregnancy and during breastfeeding is contraindicated.

    Dosing and Administration:

    Dose:

    2 capsules in the morning and 2 capsules in the evening for 10 days.

    Mode of application:

    Inside. Take capsules whole, before eating, with plenty of water.

    Side effects:

    Skin allergic reactions, such as hives, Quincke's edema and persistent erythema pigmentation.

    In cases of prolonged use of the drug, peripheral neuropathy and optic neuritis can be observed.

    When taking the drug - it is possible to increase the activity of "liver" transaminases.

    If any of the side effects indicated in the manual are aggravated, or any other side effects not indicated in the instructions are noted, you should inform the doctor immediately.

    Overdose:

    In case of an overdose, there is a risk of developing hepatotoxicity, it is necessary to monitor the activity of "liver" transaminases and prothrombin, as well as the concentration of prothrombin.

    Treatment: withdrawal of the drug, symptomatic therapy.

    Interaction:

    It is not recommended simultaneous reception with drugs containing derivatives of hydroxyquinoline.

    Special instructions:

    When the activity of "liver" transaminases increases, especially in case of liver failure, it is necessary to stop the treatment with the drug.

    Long-term use of the drug Intetriks® is inexpedient because of the risk of peripheral neuropathy.
    Effect on the ability to drive transp. cf. and fur:

    No information.

    Form release / dosage:

    Capsules.

    Packaging:

    10 capsules in a blister made of polyvinyl chloride film and aluminum foil.

    Two blisters together with instructions for use are placed in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date indicated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N011534 / 01
    Date of registration:29.06.2011
    Expiration Date:Unlimited
    The owner of the registration certificate:IPSEN PHARMA IPSEN PHARMA France
    Manufacturer: & nbsp
    Representation: & nbspIPSEN PHARMA IPSEN PHARMA France
    Information update date: & nbsp27.10.2017
    Illustrated instructions
      Instructions
      Up